flowchart TB
subgraph X[ ]
direction LR
A[Discovery<br/>~2--4 years] --> B[Preclinical<br/>~1--3 years] --> C[Phase I<br>1-2 years]
end
subgraph Y[ ]
direction LR
D[Phase II<br/>~1--3 years] --> E[Phase III<br/>~2--4 years] --> F[Regulatory Review<br/>~0.5--1+ years] --> G[Phase IV<br>Ongoing]
end
X --> Y
style A fill:#e1f5fe
style B fill:#e1f5fe
style C fill:#fff3e0
style D fill:#fff3e0
style E fill:#fff3e0
style F fill:#e8f5e9
style G fill:#e8f5e9
5 Overview of Drug Development
Bringing a new drug from laboratory discovery to pharmacy shelves is one of the most challenging, expensive, and time-consuming endeavors in modern science. Development typically spans 10 to 15 years, costs billions of dollars, and carries a high probability of failure. Yet when successful, it can transform—or even save—millions of lives.
What makes drug development so demanding is not a single obstacle, but an accumulation of constraints. Biology is uncertain: a mechanism that looks compelling in cell culture may fail in animals, and a signal seen in Phase I or II may disappear in larger, more heterogeneous Phase III populations. Safety is non-negotiable: rare adverse events can emerge only after thousands of exposures, forcing sponsors to design studies large enough to detect clinically meaningful risks. Manufacturing and quality systems must scale from milligrams in a lab to reproducible commercial production, with tight control of impurities, stability, and batch-to-batch consistency. And every step must be documented in a form that regulators can inspect and independently verify.
As a result, the process is best thought of as a sequence of risk-reduction decisions. Early work asks “does it plausibly work and is it safe enough to test?” Later stages ask “does it work better than existing options, in the patients who will actually use it, with an acceptable benefit–risk profile?” The chapters that follow map these questions onto the regulatory and operational milestones that define modern clinical development.
5.1 Development Path from Molecule to Medicine
Drug development follows a staged progression (see Figure 5.1), each phase designed to answer specific questions and manage the inherent uncertainties of working with novel therapies.
The process begins with discovery, where researchers identify a biological target—a protein, receptor, or pathway involved in disease—and search for molecules that can interact with it. This may involve screening thousands of compounds, designing molecules based on structural knowledge, or modifying natural products with known activity.
Once a promising compound is identified, preclinical research evaluates it in laboratory and animal studies. These studies establish whether the compound works as expected (does it hit the target and produce the desired biological effect?), whether it is safe enough to test in humans (what are its toxic effects in animals?), and how it behaves in the body (how is it absorbed, distributed, metabolized, and eliminated?).
Only after preclinical research provides satisfactory answers can the compound advance to clinical trials in humans.
5.2 The IND Gateway
In the United States, the transition from preclinical to clinical development requires submission of an Investigational New Drug (IND) application to the FDA. The IND is the formal request to begin testing an investigational drug in human subjects.
The IND contains three essential components. The chemistry, manufacturing, and controls section describes the drug’s composition, structure, and manufacturing process—critical information for ensuring that every batch of the investigational product is consistent and safe. The pharmacology and toxicology section summarizes the results of preclinical studies that support the proposed clinical testing. The clinical protocol section details exactly how the proposed study will be conducted.
The FDA has 30 days to review the IND. If the agency has significant concerns about safety or scientific merit, it may impose a clinical hold that prevents the study from proceeding. If no hold is issued within the 30-day period, the sponsor may begin clinical trials.
5.3 Understanding the Clinical Phases
Clinical development is traditionally divided into four phases, numbered I through IV. While these designations are useful, they can be misleading—the boundaries between phases are not sharp, and different types of studies may occur at various points in development.
The ICH E8(R1) guideline offers a complementary classification based on study objectives rather than timing (see Figure 5.2) (International Council for Harmonisation 2021). Human pharmacology studies assess tolerance, pharmacokinetics, and pharmacodynamics. Therapeutic exploratory studies explore efficacy and determine doses. Therapeutic confirmatory studies provide the definitive evidence of efficacy and safety for regulatory approval. Therapeutic use studies refine our understanding of the drug in post-marketing clinical practice.
flowchart TB
subgraph Phase1["Phase I"]
HP["Human Pharmacology"]
end
subgraph Phase2["Phase II"]
TE["Therapeutic Exploratory"]
end
subgraph Phase3["Phase III"]
TC["Therapeutic Confirmatory"]
end
subgraph Phase4["Phase IV"]
TU["Therapeutic Use"]
end
HP -->|"Some studies continue"| TE
TE -->|"Some studies may span"| TC
TC --> TU
HP -.->|"May occur throughout"| TC
HP -.->|"May occur throughout"| TU
In practice, human pharmacology studies (assessing how the drug behaves in the body) continue throughout development as new formulations are tested, drug interactions are characterized, and effects in special populations are evaluated.
ICH E8(R1) provides a classification system based on study objectives rather than just temporal phases (see Table 5.1), acknowledging that study types often overlap across phases (International Council for Harmonisation 2021). The revised guideline emphasizes Quality by Design in clinical studies, introducing the concept of Critical to Quality (CtQ) factors—those elements of trial design, conduct, and oversight that are essential to ensuring the study produces reliable evidence to answer its clinical question. CtQ factors vary by study objective: for a Phase I first-in-human study, CtQ factors might include dose escalation safety rules and pharmacokinetic sampling accuracy, while for a Phase III confirmatory trial, they typically include endpoint ascertainment, treatment adherence, and minimization of missing data.
E8(R1) also emphasizes patient-centric approaches, encouraging sponsors to incorporate patient input into development planning, endpoint selection, and trial design to ensure that studies address outcomes meaningful to patients and that participation burdens are justified by the scientific objectives.
| Study Type | Typical Phase | Primary Objectives |
|---|---|---|
| Human Pharmacology | Phase I | Assess tolerance, PK/PD, define metabolism, drug interactions |
| Therapeutic Exploratory | Phase II | Explore use for targeted indication, estimate dosing, provide basis for confirmatory design |
| Therapeutic Confirmatory | Phase III | Demonstrate/confirm efficacy, establish safety profile, provide adequate basis for marketing approval |
| Therapeutic Use | Phase IV | Refine understanding of benefit/risk in general population, identify less common adverse reactions, optimize dosing |
5.4 Regulatory Pathways
Not all drugs follow the same path to approval. The standard pathway involves completing Phase I, II, and III trials, then submitting a New Drug Application (NDA) or Biologics License Application (BLA) for FDA review. The agency targets 10 months for a standard review.
For drugs addressing serious conditions, the FDA offers several expedited programs that can significantly reduce development time and regulatory burden.
Sponsors may utilize several expedited programs to accelerate access to critical therapies. Fast Track designation provides more frequent FDA interaction and supports the rolling review of application sections for drugs addressing unmet medical needs. Breakthrough Therapy status offers even more intensive guidance for drugs showing substantial improvement over existing treatments, while Accelerated Approval allows for marketing based on surrogate endpoints that are reasonably likely to predict clinical benefit. Furthermore, Priority Review can compress the final agency review timeline from ten months to six for medications that represent significant advancements in care.
These programs can be combined. A drug with breakthrough therapy designation typically also receives fast track status and often priority review, significantly accelerating its path to patients.
5.5 The Target Product Profile
Successful drug development requires a clear vision of the end goal. The Target Product Profile (TPP) is a strategic document that describes what the final product should look like—the indication it will treat, the patient population that will use it, the dosing regimen, the claims that can be made about efficacy and safety, and how it will be positioned against competitors.
The TPP is not fixed in stone; it evolves as data accumulates and the commercial environment changes. But having a clear TPP from the outset helps align the development team and ensures that studies are designed to generate the data needed to support the intended label.
5.6 The Economics of Attrition
Drug development is an exercise in managing failure. Historic data indicated that only about 10% of drugs entering Phase I reached the market. More recent analysis from 2023-2024 suggests a slight improvement in overall success rates (~11%), driven by higher stability in Phase I and Phase III, though Phase II remains a formidable “valley of death” where nearly half of all programs fail. Table 5.2 summarizes modern success rates.
| Stage | Success Rate (2024) | Key Attrition Drivers |
|---|---|---|
| Phase I -> Phase II | ~48% | Safety signals, toxicity, strategic portfolio pruning |
| Phase II -> Phase III | ~29% | Primary bottleneck: Lack of efficacy, dose-response uncertainty |
| Phase III -> Submission | ~58% | Failure to hit endpoints, safety signals in large populations |
| Submission -> Approval | ~90% | Regulatory questions, manufacturing (CMC) issues |
| Overall: Clinic -> Market | 6-7% | Cumulative probability from Phase I start (composite success rate) |
Phase III failures are particularly costly because they occur after substantial investment. When a Phase III program fails, the sponsor has typically invested several hundred million dollars and 5 to 7 years of development time. These losses are ultimately borne by successful products and by investors.
The burden of attrition is not distributed equally across the industry. Emerging Biopharma (EBP) companies—which originate over half of all new drugs—face a significantly more difficult path to approval than their larger counterparts. According to the IQVIA 2024 report, EBPs receive Complete Response Letters (CRLs) from the FDA more frequently than larger pharmaceutical companies (IQVIA Institute for Human Data Science 2025). In 2024, while 70% of CRLs were issued for non-clinical reasons (such as manufacturing quality, product quality, or chemistry data), EBPs face particular challenges: since 2020, 41% of CRLs for EBP sponsors included clinical reasons, while the share of clinical CRLs for non-EBP companies has declined by 81% (IQVIA Institute for Human Data Science 2025). This suggests that while EBPs excel at scientific innovation, they often face challenges with both clinical evidence packages and the industrial-scale regulatory and quality infrastructure required to cross the final approval threshold.
(A detailed breakdown of R&D spending by development phase is discussed in Chapter 6.)
Analyzing the root causes of program attrition helps refine development strategy. The most common reasons for failure include a lack of therapeutic efficacy, where the drug does not meet its primary outcomes, and unacceptable safety signals that emerge during larger-scale testing. Additionally, shifts in the market may render a scientifically successful drug unviable if it cannot effectively compete with existing or emerging standards of care.